Edition:
United States

Depomed Inc (DEPO.OQ)

DEPO.OQ on NASDAQ Stock Exchange Global Select Market

8.16USD
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
$8.16
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
437,077
52-wk High
$21.37
52-wk Low
$4.32

Chart for

About

Depomed, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac... (more)

Overall

Beta: 1.26
Market Cap(Mil.): $514.19
Shares Outstanding(Mil.): 63.01
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.50 16.04
EPS (TTM): -- -- --
ROI: -- 15.11 35.70
ROE: -- 16.59 15.40

BRIEF-Depomed Announces Nucynta® Commercialization Agreement With Collegium Pharmaceutical

* DEPOMED ANNOUNCES NUCYNTA® COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL

Dec 04 2017

BRIEF-Collegium To License Rights To Commercialize Nucynta Franchise

* COLLEGIUM TO LICENSE RIGHTS TO COMMERCIALIZE NUCYNTA FRANCHISE

Dec 04 2017

BRIEF-Depomed announces Q3 loss of $0.25 per share

* Depomed inc sees ‍2017 non-gaap total revenue $380 to $385 million​

Nov 07 2017

BRIEF-Depomed and Slán Medicinal Holdings announce strategic asset transactions

* Depomed and Slán Medicinal Holdings Ltd announce strategic asset transactions

Nov 07 2017

BRIEF-PDL Biopharma announces settlement agreement with Valeant

* PDL Biopharma - ‍Valeant to pay a one-time, lump-sum payment of $13.0 million as part of settlement

Oct 30 2017

BRIEF-Depomed ‍provides information on impact of hurricane Maria to supply of NUCYNTA ER​

* Says ‍provides information on impact of hurricane Maria to supply of NUCYNTA ER​

Oct 10 2017

BRIEF-Armistice Capital LLC reports 6.4 pct passive stake in Depomed Inc

* Armistice Capital LLC reports 6.4 percent passive stake in Depomed Inc as on August 8, 2017 - SEC filing‍​‍​ Source text (http://bit.ly/2vLa8Uq) Further company coverage:

Aug 18 2017

BRIEF-Depomed Q2 loss per share $0.43

* Q2 earnings per share view $0.09 -- Thomson Reuters I/B/E/S

Aug 07 2017

BRIEF-Depomed announces intent to effect a debt refinancing

* Seeking to refinance its existing $375 million principal amount of privately placed secured senior notes

Jul 13 2017

BRIEF-Depomed chief medical officer Srinivas Rao resigns

* Depomed inc - on june 30, co entered agreement with Srinivas G. Rao, co's chief medical officer, pursuant to which dr. Rao to resign as officer of co Source text for Eikon: Further company coverage:

Jul 07 2017

Earnings vs. Estimates